Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 184, С. 117897 - 117897

Опубликована: Фев. 7, 2025

Язык: Английский

---

Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy

Journal of Controlled Release, Год журнала: 2023, Номер 361, С. 819 - 846

Опубликована: Авг. 23, 2023

Язык: Английский

---

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Advanced Healthcare Materials, Год журнала: 2024, Номер 13(13)

Опубликована: Фев. 7, 2024

Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co-stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses molecule CD40L and inhibitor PD1 elicit robust antitumor immunity for immunotherapy. The tumor antigens inherited from cytomembranes effectively stimulate dendritic (DC)-mediated activation cells, on significantly blocks PD1/PD-L1 signaling pathway, synergistically stimulating responses. Benefiting targeting ability cytomembranes, this formula shows an enhanced lymph node trafficking retention. Compared with original induces twofold DC maturation satisfactory precaution efficacy in breast mouse model. This offers simple, safe, strategy incorporating components

Язык: Английский

---

Stimuli-Responsive mRNA Vaccines to Induce Robust CD8⁺ T Cell Response via ROS-Mediated Innate Immunity Boosting

Journal of the American Chemical Society, Год журнала: 2024, Номер 146(28), С. 19218 - 19228

Опубликована: Июль 2, 2024

The messenger RNA (mRNA) vaccines hold great significance in contagion prevention and cancer immunotherapy. However, safely effectively harnessing innate immunity to stimulate robust durable adaptive immune protection is crucial, yet challenging. In this study, we synthesized a library of stimuli-responsive bivalent ionizable lipids (srBiv iLPs) with smart molecular blocks responsive esterase, H

Язык: Английский

---

Bacterial Biohybrids for Invasion of Tumor Cells Promote Antigen Cross‐Presentation Through Gap Junction

Advanced Materials, Год журнала: 2024, Номер 36(25)

Опубликована: Апрель 2, 2024

Due to inherent differences in cellular composition and metabolic behavior with host cells, tumor-harbored bacteria can discriminatorily affect tumor immune landscape. However, the mechanisms by which intracellular antigen presentation process between cells antigen-presenting (APCs) are largely unknown. The invasion of attenuated Salmonella VNP20009 (VNP) into is investigated an attempt made modulate this modifying positively charged polymers on surface VNP. It found that non-toxic chitosan oligosaccharide (COS) modified VNP (VNP@COS) bolsters formation gap junction APCs enhancing ability infect cells. On basis, a bacterial biohybrid designed promote situ cross-presentation through induced junction. This also enhances expression major histocompatibility complex class I molecules incorporation Mdivi-1 coupled VNP@COS. strategic integration serves heighten immunogenic exposure antigens; while, preserving cytotoxic potency T A strategy proposed precisely controlling function local effects microorganisms within tumors.

Язык: Английский

---

Nanotechnology-based in situ cancer vaccines: Mechanisms, design, and recent advances

Nano Today, Год журнала: 2024, Номер 56, С. 102286 - 102286

Опубликована: Май 6, 2024

Язык: Английский

---

Combination of MHI148 Targeted Photodynamic Therapy and STING Activation Inhibits Tumor Metastasis and Recurrence

ACS Applied Materials & Interfaces, Год журнала: 2024, Номер 16(23), С. 29672 - 29685

Опубликована: Май 30, 2024

Metastasis and recurrence are notable contributors to mortality associated with breast cancer. Although immunotherapy has shown promise in mitigating these risks after conventional treatments, its effectiveness remains constrained by significant challenges, such as impaired antigen presentation dendritic cells (DCs) inadequate T cell infiltration into tumor tissues. To address limitations, we developed a multifunctional nanoparticle platform, termed GM@P, which consisted of hydrophobic shell encapsulating the photosensitizer MHI148 hydrophilic core containing STING agonist 2'3'-cGAMP. This design elicited robust type I interferon responses activate antitumor immunity. The GM@P nanoparticles loaded specifically targeted cancer cells. Upon exposure 808 nm laser irradiation, MHI148-loaded produced toxic reactive oxygen species (ROS) eradicate through photodynamic therapy (PDT). Notably, PDT stimulated immunogenic death (ICD) foster potency immune responses. Furthermore, superior photoacoustic imaging (PAI) capabilities enabled simultaneous visualization diagnostic therapeutic procedures. Collectively, our findings uncovered that combination activation facilitated more conducive microenvironment, characterized enhanced DC maturation, CD8+ cells, proinflammatory cytokine release. strategy local augment systemic effects, offering promising approach suppress growth, inhibit metastasis, prevent recurrence.

Язык: Английский

---

Bioactive metal-based nanomedicines for boosting anti-tumor immunity: Advance, challenge, and perspective

Coordination Chemistry Reviews, Год журнала: 2024, Номер 517, С. 215969 - 215969

Опубликована: Июнь 10, 2024

Язык: Английский

---

A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Авг. 29, 2024

Pathogen-mimicking nanoparticles have emerged at the forefront of vaccine delivery technology, offering potent immune activation and excellent biocompatibility. Among these innovative carriers, mannan, a critical component yeast cell walls, shows promise as an exemplary carrier. Nevertheless, it faces challenges like unpredictable immunogenicity, rapid elimination, limited antigen loading due to high water solubility. Herein, mannan with varying carbon chain ratios is innovatively modified, yielding series dodecyl chains modified (Mann-C

Язык: Английский

---

Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer

Journal of Controlled Release, Год журнала: 2024, Номер 378, С. 438 - 459

Опубликована: Дек. 21, 2024

Cancer vaccines are promising therapeutic approaches to enhance specific T-cell immunity against most solid tumors. By stimulating anti-tumor immunity, clearing minimal residual disease, and minimizing adverse effects, these target tumor cells effective when combined with immune checkpoint blockade or other immunotherapies. However, the development of cell-based faces quality issues due poor immunogenicity, heterogeneity, a suppressive microenvironment, ineffective delivery methods. In contrast, extracellular vesicles (EVs), naturally released by cells, considered ideal drug carriers vaccine platforms. EVs offer highly organ-specific targeting, induce broader more responses, demonstrate superior tissue ability. The EV is crucial for advancing cancer immunotherapy. Compared vaccines, produced under Good Manufacturing Practices (GMP) advantages such as high safety, ease preservation transport, wide range sources. This review summarizes latest research findings on potential applications in this field. It also highlights novel neoantigens cancer.

Язык: Английский

---